Clinical Report: Meet the Team: Shernan Holtan, MD

Overview

Revise to include Dr. Holtan's dual focus on prevention and treatment strategies for GVHD.

Background

Graft versus host disease remains a significant complication following allogeneic stem cell transplantation, impacting patient outcomes and quality of life. Recent advancements in prophylactic strategies, particularly the use of post-transplant cyclophosphamide, have transformed GVHD management. Understanding these developments is crucial for healthcare professionals involved in hematology and oncology.

Data Highlights

No numerical data available in the source material.

Key Findings

• Dr. Holtan's research has led to a significant reduction in GVHD incidence from approximately 50% to 5-10% with the use of post-transplant cyclophosphamide.
• Clinical trials conducted by Dr. Holtan have transformed GVHD prophylaxis, marking the first major change in nearly 40 years.
• Current research focuses on combining immunotherapy with anti-leukemia effects to address both relapse and GVHD.
• Emphasis on improving patient care includes attention to nutrition and exercise during recovery from transplantation.
• Dr. Holtan aims to reduce recovery time by 50% through innovative medical and supportive care strategies.

Clinical Implications

Healthcare providers should be aware of the evolving strategies in GVHD prevention, particularly the role of post-transplant cyclophosphamide. Additionally, integrating supportive care measures can enhance patient recovery and overall quality of life during and after treatment.

Conclusion

Dr. Holtan's contributions to GVHD research and patient care represent a significant advancement in the field of hematology. Continued focus on innovative therapies and supportive care will be essential for improving outcomes in patients undergoing stem cell transplantation.

References

1. The ASCO Post, 2014 -- Holy Name Medical Center of New Jersey Welcomes Sharyn N. Lewin, MD, FACS, and Phyllis Tarallo, DNP, DCC
2. The ASCO Post, 2014 -- The American Society of Hematology Elects New Leadership
3. roswell park comprehensive cancer center -- Meet the Team: Eleanor Fallon, MD
4. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation - ScienceDirect
5. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis - PMC
6. roswell park comprehensive cancer center — Meet the Team: Rohit Gosain, MD
7. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation - ScienceDirect
8. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis - PMC
9. REACH2: ruxolitinib for refractory aGvHD - PubMed